Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (2)
  • P-gp
    (2)
  • Bcl-2 Family
    (1)
  • COX
    (1)
  • HIV Protease
    (1)
  • SARS-CoV
    (1)
  • UGT
    (1)
  • Others
    (3)
Filter
Search Result
Results for "

coadministration

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    6
    TargetMol | All_Pathways
  • Natural Products
    3
    TargetMol | Natural_Products
  • Reference Standards
    1
    TargetMol | Standard_Products
Lopinavir
ABT-378
T1623192725-17-0
Lopinavir (ABT-378) is a peptidomimetic HIV protease inhibitor effective against HIV protease with the Val 82 mutation. It is less affected by serum protein binding compared to the structurally related drug ritonavir.
  • $41
In Stock
Size
QTY
TargetMol | Citations Cited
FY26
FY-26, FY 26
T318991255143-82-8
FY26 is a potent Os(II) anticancer drug candidate, exerts its activity by generating reactive oxygen species and disrupting the redox balance in cancer cells Coadministration of FY26 and nontoxic doses of L-BSO allows the potentiation of its anticancer ac
  • $1,520
Inquiry
Size
QTY
Jaceosidin
T382418085-97-7
Jaceosidin has anti-oxidative activity. Jaceosidin has anti-inflammatory activity, also a microglial inhibitor with anti-neuroinflammation activity. aceosidin has anticancer activity, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the Cd
  • $44
In Stock
Size
QTY
KR30031
T69956205535-74-6
KR30031 is a novel P-glycoprotein inhibitor with potential anticancer activity. KR30031 is a verapamil analog with fewer cardiovascular effects. The ability of KR-30031 to reduce this efflux transport is equal to that of verapamil, a well-known P-glycoprotein inhibitor. The bioavailability of paclitaxel could be enhanced by coadministration of a P-glycoprotein inhibitor, KR-30031.
  • $1,520
6-8 weeks
Size
QTY
Jaceosidin (Standard)
TMSM-314718085-97-7
Jaceosidin (Standard) is a reference standard for research and analysis in studies involving Jaceosidin. Jaceosidin has anti-oxidative activity. Jaceosidin has anti-inflammatory activity, also a microglial inhibitor with anti-neuroinflammation activity. aceosidin has anticancer activity, modulates the ERK/ATM/Chk1/2 pathway, leading to inactivation of the Cdc2-cyclin B1 complex, followed by G2/M cell cycle arrest in endometrial cancer cells. Jaceosidin has immunosuppressive effect through inhibiting T cell proliferation and activation, which is closely associated with its potent down-regulation of the IFN-γ/STAT1/T-bet signaling pathway. The pharmacokinetics of Jaceosidin may be dramatically affected by polymorphic CYP1A2, UGT1A1, and UGT1A7 responsible for the metabolism of Jaceosidin or by the coadministration of relevant CYP1A2 or UGT inhibitors or inducers.
  • $1,230
7-10 days
Size
QTY
Phellamurin
TN476152589-11-4
Phellamurin inhibits intestinal P-glycoprotein in a dose-dependent manner, there is a serious interaction occurred between Phellamurin with cyclosporin, to ensure the efficacy of cyclosporin, we suggest that the coadministration of Phellamurin or Phellode
  • $166
In Stock
Size
QTY